Cargando…

Exploring the Mechanism and Suggesting Combination Therapies for HDAC Inhibitors in Androgen Receptor-Null Prostate Cancer Using Multivariate Statistical Analysis and Data Mining Techniques

Previously, we showed that novel histone deacetylase (HDAC) inhibitors, N1-hydroxy-N(8)-(4-(pyridine-2-carbothioamido)phenyl)octanediamide (Jazz90) and [chlorido(η(5)-pentamethylcyclopentadienyl)(N1-hydroxy-N8-(4-(pyridine-2-carbothioamido-κ(2)N, S)phenyl)octanediamide)rhodium(III)] chloride (Jazz16...

Descripción completa

Detalles Bibliográficos
Autores principales: Rana, Zohaib, Rosengren, Rhonda J, Smith, Paul F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772946/
https://www.ncbi.nlm.nih.gov/pubmed/36570326
http://dx.doi.org/10.1177/11779322221145428
_version_ 1784855091519422464
author Rana, Zohaib
Rosengren, Rhonda J
Smith, Paul F
author_facet Rana, Zohaib
Rosengren, Rhonda J
Smith, Paul F
author_sort Rana, Zohaib
collection PubMed
description Previously, we showed that novel histone deacetylase (HDAC) inhibitors, N1-hydroxy-N(8)-(4-(pyridine-2-carbothioamido)phenyl)octanediamide (Jazz90) and [chlorido(η(5)-pentamethylcyclopentadienyl)(N1-hydroxy-N8-(4-(pyridine-2-carbothioamido-κ(2)N, S)phenyl)octanediamide)rhodium(III)] chloride (Jazz167), have cytostatic and anti-angiogenic effects in androgen receptor-negative prostate cancer cells and are also non-toxic in BALB/c mice. However, only univariate statistical analysis was carried out to determine the role of individual proteins. In this study, multivariate statistical analyses (MVAs) and data mining procedures were carried out with the objective of determining the molecular networks that explain the growth inhibitory potential of Jazz90 and Jazz167 in PC3 cells and to determine potential inhibitors that can be used in combination with these HDAC inhibitors. Lasso regression revealed that angiogenic factors, vascular endothelial growth factor-A (VEGF-A), and vascular endothelial growth factor receptor-2 (VEGFR-2), alongside HDAC inhibition, predicted the reduction in cell number with an adjusted R(2) value of 0.99 following Jazz90 treatment, whereas VEGFR-2, acetylation of histone-3, and HDAC inhibition predicted cell number with an adjusted R(2) value of 0.84 following Jazz167 treatment. These results were further followed up with ridge regression, hierarchical cluster analysis, random forest classification (RFC), and support vector machines. RFC and support vector machines also predicted the treatment groups with a 100% accuracy. MVAs also revealed that Jazz90 should be examined in combination with epithelial to mesenchymal transitioning inhibitors, such as simvastatin and olaparib, whereas Jazz167 should be examined with venetoclax or navitoclax. Future studies should also address the roles of VEGF-A and VEGFR-2 in cellular proliferation, whereas p27 function should be examined for its role in PC3 cell migration.
format Online
Article
Text
id pubmed-9772946
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-97729462022-12-23 Exploring the Mechanism and Suggesting Combination Therapies for HDAC Inhibitors in Androgen Receptor-Null Prostate Cancer Using Multivariate Statistical Analysis and Data Mining Techniques Rana, Zohaib Rosengren, Rhonda J Smith, Paul F Bioinform Biol Insights Original Research Article Previously, we showed that novel histone deacetylase (HDAC) inhibitors, N1-hydroxy-N(8)-(4-(pyridine-2-carbothioamido)phenyl)octanediamide (Jazz90) and [chlorido(η(5)-pentamethylcyclopentadienyl)(N1-hydroxy-N8-(4-(pyridine-2-carbothioamido-κ(2)N, S)phenyl)octanediamide)rhodium(III)] chloride (Jazz167), have cytostatic and anti-angiogenic effects in androgen receptor-negative prostate cancer cells and are also non-toxic in BALB/c mice. However, only univariate statistical analysis was carried out to determine the role of individual proteins. In this study, multivariate statistical analyses (MVAs) and data mining procedures were carried out with the objective of determining the molecular networks that explain the growth inhibitory potential of Jazz90 and Jazz167 in PC3 cells and to determine potential inhibitors that can be used in combination with these HDAC inhibitors. Lasso regression revealed that angiogenic factors, vascular endothelial growth factor-A (VEGF-A), and vascular endothelial growth factor receptor-2 (VEGFR-2), alongside HDAC inhibition, predicted the reduction in cell number with an adjusted R(2) value of 0.99 following Jazz90 treatment, whereas VEGFR-2, acetylation of histone-3, and HDAC inhibition predicted cell number with an adjusted R(2) value of 0.84 following Jazz167 treatment. These results were further followed up with ridge regression, hierarchical cluster analysis, random forest classification (RFC), and support vector machines. RFC and support vector machines also predicted the treatment groups with a 100% accuracy. MVAs also revealed that Jazz90 should be examined in combination with epithelial to mesenchymal transitioning inhibitors, such as simvastatin and olaparib, whereas Jazz167 should be examined with venetoclax or navitoclax. Future studies should also address the roles of VEGF-A and VEGFR-2 in cellular proliferation, whereas p27 function should be examined for its role in PC3 cell migration. SAGE Publications 2022-12-19 /pmc/articles/PMC9772946/ /pubmed/36570326 http://dx.doi.org/10.1177/11779322221145428 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Rana, Zohaib
Rosengren, Rhonda J
Smith, Paul F
Exploring the Mechanism and Suggesting Combination Therapies for HDAC Inhibitors in Androgen Receptor-Null Prostate Cancer Using Multivariate Statistical Analysis and Data Mining Techniques
title Exploring the Mechanism and Suggesting Combination Therapies for HDAC Inhibitors in Androgen Receptor-Null Prostate Cancer Using Multivariate Statistical Analysis and Data Mining Techniques
title_full Exploring the Mechanism and Suggesting Combination Therapies for HDAC Inhibitors in Androgen Receptor-Null Prostate Cancer Using Multivariate Statistical Analysis and Data Mining Techniques
title_fullStr Exploring the Mechanism and Suggesting Combination Therapies for HDAC Inhibitors in Androgen Receptor-Null Prostate Cancer Using Multivariate Statistical Analysis and Data Mining Techniques
title_full_unstemmed Exploring the Mechanism and Suggesting Combination Therapies for HDAC Inhibitors in Androgen Receptor-Null Prostate Cancer Using Multivariate Statistical Analysis and Data Mining Techniques
title_short Exploring the Mechanism and Suggesting Combination Therapies for HDAC Inhibitors in Androgen Receptor-Null Prostate Cancer Using Multivariate Statistical Analysis and Data Mining Techniques
title_sort exploring the mechanism and suggesting combination therapies for hdac inhibitors in androgen receptor-null prostate cancer using multivariate statistical analysis and data mining techniques
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772946/
https://www.ncbi.nlm.nih.gov/pubmed/36570326
http://dx.doi.org/10.1177/11779322221145428
work_keys_str_mv AT ranazohaib exploringthemechanismandsuggestingcombinationtherapiesforhdacinhibitorsinandrogenreceptornullprostatecancerusingmultivariatestatisticalanalysisanddataminingtechniques
AT rosengrenrhondaj exploringthemechanismandsuggestingcombinationtherapiesforhdacinhibitorsinandrogenreceptornullprostatecancerusingmultivariatestatisticalanalysisanddataminingtechniques
AT smithpaulf exploringthemechanismandsuggestingcombinationtherapiesforhdacinhibitorsinandrogenreceptornullprostatecancerusingmultivariatestatisticalanalysisanddataminingtechniques